ClinicalTrials.gg
CompletedNCT04323033PERSUpdated Mar 14, 2022

Safety and Efficacy of Peripheral, Cobalt-chromium Sirolimus Eluting Stent (PERS) Versus Cobalt-chromium Stent (Neptune C)

An interventional study of PERS stent and NEPTUN C stent in Peripheral Arterial Disease, sponsored by Balton Sp.zo.o.. Completed at 3 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-14.

Sponsored by Balton Sp.zo.o. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Mar 2019, registered Oct 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Peripheral Arterial Disease with a site in Poland — 7 open to participants now, 9 under way, 3 of them phase 3. Peripheral Arterial Disease · Poland.

Enrollment
25th of 28
40 · median 220
Started
2019
with 1 other
No phase
16 of 31
4 open now
Registered
18th of 31
by date
Lead sponsor
3 of 31
Balton Sp.zo.o.

Among the 31 studies in Peripheral Arterial Disease with a site in Poland, this one is the 25th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2019, is one of 16 with no phase, and was the 18th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

7 of the 31 studies in Peripheral Arterial Disease with a site in Poland are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Peripheral Arterial Disease with a site in Poland, or all of them as a file.
02

Study summary

The aim of this study is to assess the safety and efficacy of PAD treatment by revascularization with new cobalt-chromium sirolimus stent implantation, which is expandable on balloon PERS (CoCr SES) compared to cobalt-chromium balloon-expandable (Neptun C) stent (CoCr BMS) in patients with symptomatic iliac arteries disease requiring revascularization.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. De novo lesion or restenosis without previously implanted stent, in a common or external iliac artery with a reference diameter of 5 to 12 mm, length up to 10 cm and stenosis ≥ 50% and ≤ 99% (in quantitative assessment by peripheral angiography), which may be treated with one stent or total occlusion of vessels up to 50 mm long.
  2. Ability to cross the lesion with guidewire (assessed during diagnostic angiography).
  3. ABI ankle-brachial index \<0.9.
  4. Signs of lower limb ischemia based on the Rutherford scale in the range from 2 to 4.
  5. Age ≥ 18 years.
  6. Patient signed form.

Exclusion criteria

Exclusion Criteria:

  1. less than two years.
  2. Chronic kidney disease in stage III-V.
  3. Lesion in the previously implanted by-pass.
  4. Target lesion is a chronic total occlusion of significant length, not eligible for percutaneous revascularization.
  5. Acute lower limb ischemia.
  6. Stenosis (> 50%) or occlusion proximally to the lesion being treated.
  7. Angiographically confirmed thrombus in the lesion to be treated.
  8. Treatment requires an atherectomy to deliver stent to treated lesion.
  9. Known allergy or to clopidogrel.
  10. Hemorrhagic stroke in the last three months.
  11. for acetylsalicylic acid (hypersensitivity, hemorrhagic diathesis).
  12. Pregnancy or women of not using effective .
  13. Active inflammation at the planned access site.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    PERS stent

    20 Patients will receive PERS stent

    Device: PERS stent

  • Active comparator
    NEPTUN C stent

    20 Patients will receive NEPTUN C stent

    Device: NEPTUN C stent

Interventions

  • DevicePERS stent

    PERS® is a cobalt-chromium stent, made of cobalt-chromium alloy with drug (Sirolimus) and biodegradable polymer controlling drug elution. The length of the stent is selected to cover the treated lesion with a margin of 5 mm proximal and distal, while the diameter of the stent will be selected based on the QVA measurement (balloon to vessel ratio 1:1).

  • DeviceNEPTUN C stent

    Neptun C is balloon-expanding cobalt-chromium stent.

06

What researchers measure

Primary outcomes

  1. Occurrence of MAE

    Occurrence of major adverse event (MAE) in 12 months follow up, defined as death related to stent implantation of procedure, amputation above metatarsus in treated limb due to vascular complication or/and reintervention in treated lesion (TLR).

    Time frame: 12 months FU

Secondary outcomes

  1. Vessel patency

    Vessel patency 30 days, 6 and 12 months after the initial procedure assessed by Dupplex Doppler

    Time frame: 30 days, 6 months and 12 months FU

  2. Success of implanting the device

    Success of implanting the device, defined as residual stenosis ≤30% in angiographic assessment.

    Time frame: Directly after implantation, at the end of endovascular index procedure

  3. Procedural success

    Procedural success, defined as residual stenosis ≤30% in angiographic assessment and lack of procedurę related SAE.

    Time frame: Up to 7 days after procedure

  4. Clinical success

    Clinical success, defined as improvement in Rutherford classification for at least 1 point.

    Time frame: During follow-up visits: 30 days, 6 months and 12 months

  5. ABI (ankle-brachial index) change

    ABI (ankle-brachial index) change after 30 days and 12 months

    Time frame: 30 days and 12 months FU

  6. Mortality rate

    Mortality rate after 30 days, 6 months and 12 months (cardiovascular deaths)

    Time frame: 30 days, 6 months and 12 months FU

  7. Artery patency in Duplex Doppler USG: Maximum velocity flow

    Maximum velocity flow assessed by Dupplex Doppler

    Time frame: 30 days, 6 months and 12 months FU

  8. Artery patency in Duplex Doppler USG: % of diameter stenosis

    % of diameter stenosis (DS in target lesion) assessed by Dupplex Doppler

    Time frame: 30 days, 6 months and 12 months FU

07

Study locations

3 sites
  • Małopolskie Centrum Sercowo-Naczyniowe PAKS American Heart of Poland S.A.
    Chrzanów, 32-500, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1
    Lublin, 20-081, Poland
  • Szpital Eskulap Centrum Leczenia Chorób Serca i Naczyń
    Osielsko, 86-031, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Oct 2020, 19 months.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's 19 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2019
First posted
Mar 26, 2020
StartActual
Mar 13, 2019
Primary completionActual
Oct 31, 2020
CompletionActual
Nov 9, 2021
Last update
Mar 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04323033
Lead sponsor
Balton Sp.zo.o.
Collaborators
KCRI
Responsible party
Sponsor
First posted
Mar 26, 2020
Start date
Mar 13, 2019
Primary completion
Oct 31, 2020
Completion
Nov 9, 2021
Last update
Mar 14, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion